valuationLAB Issues Research Report on Addex Therapeutics

Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation

Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting

Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain

Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia

Addex Annual General Meeting Scheduled for 11 June 2015

Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia

Addex Therapeutics Reports 2014 Financial Results

Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017

Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation